Philip Morris
Nicotine Patch Overview
Fields
- Area
- WINOKUR,MATT/OFFICE
- Type
- SPCH, SPEECH, PRESENTATION
- CHAR, CHART, GRAPH, TABLE, MAPS
- Master ID
- 2025497087/7200
Related Documents:- 2025497087 Worldwide Regulatory Affairs
- 2025497088 Worldwide Regulatory Affairs Role
- 2025497089 Role of Science
- 2025497090-7101 Eu Action on Smoking in the Workplace and in Public Places
- 2025497102 Status of Ets Related Smoking Restrictions in Europe
- 2025497121-7133 the Activist Movement
- 2025497134 Selected International Organizations and Applications
- 2025497135-7140 Selected Pmi Issues Management Projects
- 2025497141 Mission Statement
- 2025497142 Objectives
- 2025497143 Mission Statement
- 2025497144 Pmi Global Corporate Affairs Issues
- 2025497145-7156 Worldwide Corporate Affairs Issues and Objectives
- 2025497157-7185 Corporate Affairs Europe Working Objectives
- 2025497186-7187
- 2025497188-7193 Selected Issues Management Projects 920100 - 920500
- 2025497194 Fax Transmission
- 2025497195-7200 Issues of Interest to the Tobacco Industry
- Named Organization
- Alza
- American Cyanamid
- Ciba Geigy
- Cygnos Therapeutic
- Elan
- FDA, Food and Drug Administration
- Kabi Pharmacia
- Marion Merrell Dow
- Roper, Roper Org
- Warner Lambert
- American Cyanamid
- Request
- Stmn/R4-005
- Litigation
- Stmn/Produced
- Site
- N421
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- gmz88e00
Document Images
NICOTINE PATCH
OVERVIEW
eoi4svszoz

CURRENT PERFORMANCE
Nicotine patch sales have exceeded initial expectations. 1992
estimated sales $600 - $800 million with some predicting results
close to $880 million. 1993 figures to be $1 billion.
Strong demand fueled in part by heavy ad spending featuring TV
and print. Magazine only spending was $18.5 million for
category with about $3-$5 million for TV in January - March 1992.
Patch orders outstripping current capacity prompting plant
expansion, new machine installation.
Profit margins estimated at 15% after taxes - roughly in line with
cigarette industry.
Patch treatment per quitter is approximately $350.00.
tdT4GVSZOz

COMpETITION
Habitrol
Ciba Geigy
60% SOM
* FDA approval 9/27/91
Nicoderm
Alza/Marion Merrel Dow
27% SOM
FDA approval 9/18/91
Prostep
Elan/American Cyanimide
13% SOM
FDA approval 1/28/92
Nicotrol
Kabi Pharmacia/Warner Lambert/
Cygnos Therapeutic
Not in market
SUTL6VSZOZ

PATCH EFFECTIVENESS
Consumer endorsement high with 88% who would
recommend to a friend.
Initial clinical results indicate that the nicotine patch was
somewhat more effective against placebos. Success rates
for nicotine patch 17%-36% vs placebos at 4%-26% in
impacting smoking abstinence.
Some sort of behavior modification was administered
during the clinical tests. Without some degree of
psychological therapy, many experts warn that the
nicotine patch is powerless.
Nicotine gum achieved comparable results vis a vis
placebos. Yet, treatment is often demanding.
Up to 30 sticks/day
Very gradual dose reduction
Required to keep product between cheek and gum
9nT46tszoz

40
35
c 25
J
W
Z_ 15
~
0
U 10
z
-
D.-
I-
o Cigarette'
* 2 mg nicotine gums
0
2
I
I
I
4 6 8
TIME (min)
L
I0
12
W,

2a25497108
r
20
HABITROL PATCH
m
V
5
0
.
0
0
10
.
20
IN
.
30

185z
165
CigarE tte
Plnsma
nicotine
( nrnof/1)
145-
y
125-
105~
85~
.
65'
45-1
,
0 }0
.
n"
2C 30 40 .50 f 0
T i:. e ( rnin )
NNS t
Cigarette Nicotne gum l
Avcral,e plasma nicotine conccntrationa of three suEyects after smokinr-a -
ci~arcttc, takins~. nasal nicotinc solution (NNS), an.d chcw-ing nicotine gum.
i)oscs of nicotine were 2 mg for nasaI nicotine solution and nicotine Fum
ancl zvcris~cd 197 n:g (sce tcxt) for the cigarettc.
Convcrsiorr:.. St :a trocliriarrnl ur.its--tiirntinc : I ntnal/1.;; U 16 nglml.

PATCH CLINICAL RESULTS
Post Treatment Behavioral Objectively
Patch Brand Duration % Abstain Therapy Validated
Patch Placebo
Habitrol 3 months 36 23 Yes No
Nicoderm 6 months 31 8 Yes No
Nicotrol* 1 year 17 4 Yes Yes
Prostep
*16 hour patch 1 year 26 26 Yes Yes
ntZLGtSZOz

POLACRILEX (NICOTINE GUM)
CLINICAL RESULTS
Post treatment Objectively
Dose Tar et Duration % Abstain Validated
Gum Placebo
2mg Low nicotine
dependent 1 year 40 24 Yes
4mg High nicotine
dependent 1 year 44 12 Yes
t IY46bSZOz

METHOD USED TO QUIT SMOKING
PAST 3 MONTH QUITTERS
Stopped All
At Once
Nicotine
Patch
Stopped
Gradually
Nicotine
Gum
Stopped
Smoking
Class
Hypnosis
SOURCE: Smoker Tracking Study
85 ® Jan/Feb
, April
~ May
z TzLsVszoz

AWARENESS OF NICOTINE PATCH
PAST 3 MONTH QUITTERS
APRIL
Source: Smoker Tracking,Study
MAY
ejT46tszoz

RECOMMEND NICOTINE PATCH TO A FRIEND
TOTAL PATCH USERS
Would recommend
® Would not recommend
p Don't Know
SOURCE: Smoker Tracking Study
VjT46tszoz

EFFECTIVENESS OF NICOTINE PATCH
TOTAL PATCH USERS
Very effective
Somewhat effective
Not at all effective
SOURCE: Smoker Tracking Study
szUsVszoz

NICOTINE PATCH USAGE
TOTAL PATCH USERS
Doctor suggested use
Asked Doctor to
prescribe it
Q Don't Know
SOURCE: Smoker Tracking Study.
9TZL6tSZOZ

SOURCE OF INITIAL AWARENESS FOR NICOTINE PATCH
TOTAL PATCH USERS
Friend/Relative
. Doctor
TV Advertising
Newspaper/ Other
Magazine
Article
SOURCE: Smoker Tracking Study
41146vszoz

IMPACT ON QUITTING
Approximately 23% or 11.7 million smokers try to
quit every year. 3.5 million claim to quit in the past
year. 2.4 million stay quit for the year.
Nicotine patch could potentially accelerate decline of
cigarette industry in several ways
Encourage more smokers to try to quit
Enable more triers to actually quit
Enhance success rate of quitters who
permanently leave smoking
siizst7sz0z

I
1992 QUITTING OVERVIEW
Total
Smokers Tried to Quit
Past Year Claimed to Quit
Past Year Gross Industry
Smoker Loss
Smokers
(millions)
52.0
11.7
3.5
2.4
o~a 100 22.5 6.8 4.6
GTz4Gtszoz

12MM QUITTING RATES
PAST YEAR QUITTERS
10
9
8
7.5
6.8
6
5
J F M A M J A S O D J F M A M J A S O D J F M A
1990 1991 1992
SOURCE: Roper
Oz,lLGtsz0z
